Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Moderna Inc (MRNA)

Moderna Inc (MRNA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 46,548,328
  • Shares Outstanding, K 383,240
  • Annual Sales, $ 6,848 M
  • Annual Income, $ -4,714 M
  • 60-Month Beta 1.66
  • Price/Sales 6.87
  • Price/Cash Flow N/A
  • Price/Book 3.67
Trade MRNA with:

Options Overview Details

View History
  • Implied Volatility 61.81% ( +5.02%)
  • Historical Volatility 51.08%
  • IV Percentile 93%
  • IV Rank 78.46%
  • IV High 67.77% on 10/27/23
  • IV Low 40.11% on 09/14/23
  • Put/Call Vol Ratio 0.36
  • Today's Volume 67,583
  • Volume Avg (30-Day) 38,355
  • Put/Call OI Ratio 0.99
  • Today's Open Interest 416,401
  • Open Int (30-Day) 381,935

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 21 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -3.47
  • Number of Estimates 12
  • High Estimate -3.09
  • Low Estimate -4.20
  • Prior Year -3.62
  • Growth Rate Est. (year over year) +4.14%

Price Performance

See More
Period Period Low Period High Performance
1-Month
114.02 +6.53%
on 07/02/24
148.84 -18.40%
on 06/13/24
-26.26 (-17.78%)
since 06/12/24
3-Month
99.30 +22.32%
on 04/22/24
170.47 -28.75%
on 05/24/24
+16.32 (+15.52%)
since 04/12/24
52-Week
62.55 +94.18%
on 11/02/23
170.47 -28.75%
on 05/24/24
-4.46 (-3.54%)
since 07/12/23

Most Recent Stories

More News
Is Moderna Stock a Buy?

The biotech is proving that it's not a pandemic stock.

MRNA : 121.46 (-1.11%)
Moderna And Mitsubishi Tanabe Pharma Corporation Enter Joint Agreement to Promote Moderna’s mRNA Respiratory Vaccine Portfolio in Japan, Including COVID-19 Vaccines

CAMBRIDGE, MA AND OSAKA, JAPAN / ACCESSWIRE / July 8, 2024 / Moderna, Inc. (Nasdaq:MRNA) and Mitsubishi Tanabe Pharma Corporation today announced that the companies have entered into a joint agreement...

MRNA : 121.46 (-1.11%)
The US will pay Moderna $176 million to develop an mRNA pandemic flu vaccine

The U.S. government will pay the vaccine maker Moderna $176 million to accelerate development of a pandemic influenza vaccine

MRNA : 121.46 (-1.11%)
Tesla, Archer Aviation rise; Eli Lilly falls, Tuesday, 7/2/2024

Stocks that traded heavily or had substantial price changes on Tuesday: Tesla, Archer Aviation rise; Eli Lilly falls

SCCO : 115.20 (+0.53%)
TYL : 523.08 (+1.71%)
MRNA : 121.46 (-1.11%)
LLY : 948.40 (+1.53%)
PARAA : 21.40 (-0.14%)
ACHR : 5.05 (+10.50%)
TSLA : 248.23 (+2.99%)
US will pay vaccine maker Moderna $176 million to develop an mRNA-based pandemic flu vaccine

US will pay vaccine maker Moderna $176 million to develop an mRNA-based pandemic flu vaccine

MRNA : 121.46 (-1.11%)
Nasdaq Futures Fall as Micron’s Sales Outlook Disappoints, U.S. GDP Data and Nike Earnings in Focus

September Nasdaq 100 E-Mini futures (NQU24) are trending down -0.23% this morning as an underwhelming sales forecast from chipmaker Micron weighed on sentiment, while investors awaited a flurry of U.S....

NQU24 : 20,524.00s (+0.40%)
MU : 133.55 (+2.55%)
FDX : 299.02 (-0.17%)
AAPL : 230.54 (+1.31%)
WHR : 109.85 (+1.30%)
MRNA : 121.46 (-1.11%)
NKE : 73.42 (+0.04%)
MKC : 71.45 (+0.37%)
WBA : 11.50 (+0.61%)
AYI : 244.54 (+0.46%)
HMB.S.DX : 175.550 (+2.83%)
LEVI : 19.11 (-0.05%)
2 Stocks Down More Than 30% to Buy Right Now

These stocks have suffered as the demand for their biggest product -- the coronavirus vaccine -- waned.

MRNA : 121.46 (-1.11%)
PFE : 28.92 (+0.91%)
Stocks Post Modest Gains on Strength in FedEx and Amazon

The S&P 500 Index ($SPX ) (SPY ) Wednesday closed up +0.16%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +0.04%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.25%. Stock indexes on...

$SPX : 5,615.35 (+0.55%)
SPY : 559.99 (+0.63%)
$DOWI : 40,000.90 (+0.62%)
DIA : 400.32 (+0.68%)
$IUXX : 20,331.49 (+0.59%)
QQQ : 494.82 (+0.59%)
ZNU24 : 111-060s (+0.03%)
FDX : 299.02 (-0.17%)
UPS : 142.35 (+2.97%)
ODFL : 190.22 (+1.85%)
JBHT : 166.16 (+1.75%)
AMZN : 194.49 (-0.29%)
Is Moderna Stock Outperforming the S&P 500?

Moderna recently outperformed the S&P 500, and Wall Street analysts are moderately optimistic about the stock’s prospects.

MRNA : 121.46 (-1.11%)
PFE : 28.92 (+0.91%)
$SPX : 5,615.35 (+0.55%)
Strength in Chip Stocks Pushes the S&P 500 to a New Record High

The S&P 500 Index ($SPX ) (SPY ) Tuesday closed up +0.25%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +0.15%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.03%. Stock indexes Tuesday...

$SPX : 5,615.35 (+0.55%)
SPY : 559.99 (+0.63%)
$DOWI : 40,000.90 (+0.62%)
DIA : 400.32 (+0.68%)
$IUXX : 20,331.49 (+0.59%)
QQQ : 494.82 (+0.59%)
ZNU24 : 111-060s (+0.03%)
NVDA : 129.24 (+1.44%)
AMAT : 243.40 (+0.89%)
QCOM : 202.43 (+1.29%)
MCHP : 92.61 (+0.56%)
KLAC : 857.72 (+0.56%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Moderna, Inc. is a clinical-stage pharmaceutical company, primarily focused on discovering and developing messenger RNA (mRNA) based therapies. The company's mRNA based COVID-19 vaccine, Spikevax (mRNA-1273), is approved for use in adults in the United States. The vaccine is also authorized for emergency...

See More

Key Turning Points

3rd Resistance Point 135.28
2nd Resistance Point 132.33
1st Resistance Point 126.90
Last Price 121.46
1st Support Level 118.52
2nd Support Level 115.57
3rd Support Level 110.14

See More

52-Week High 170.47
Fibonacci 61.8% 129.24
Last Price 121.46
Fibonacci 50% 116.51
Fibonacci 38.2% 103.78
52-Week Low 62.55

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar